Strategic Partnerships Olink has recent high-profile collaborations with Regeneron Genetics Center and Evotec, signaling strong partner demand for proteomics platforms. This suggests sales opportunities through licensed partnerships, co-development programs, and expansion of existing collaborations to deepen data access and platform adoption.

Enterprise Scale With a revenue range of $250M-$500M and a sizable workforce, Olink operates at an enterprise scale with complex buying cycles. Target large biopharma and contract research organizations to upsell multi-site deployments, enterprise licenses, and extended data services.

Data Enablement Olink emphasizes validated, scalable proteomic data across thousands of studies. Position solutions around large population studies, translational research, and data-driven decision support to win multi-year instrument and data access agreements.

Acquisition Landscape Market activity shows potential consolidation (Thermo Fisher acquisition signals buyer interest). Use this to tailor messaging around strategic fit, integration capabilities, and continuity of support for customers during any transitional periods.

Platform Synergy Tech stack highlights include HIPAA compliance and scalable data platforms. Leverage these capabilities to address regulated environments, expand into clinical proteomics programs, and offer compliant data management and integration services to life sciences organizations.